Recent News Releases

Sep 13, 2018

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to...

Sep 11, 2018

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform...

Sep 10, 2018

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform...

Sep 7, 2018

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and...

See All News Releases

Financial Reports

Quarterly and Annual Financial Results

Fourth quarter, 2018 (full year ended June 30, 2018)
Third quarter, 2018 (quarter ended March 31, 2018)
Second quarter, 2018 (quarter ended December 31, 2017)
First quarter, 2018 (quarter ended September 30, 2017)
Fourth quarter, 2017 (full year ended June 30, 2017)
Third quarter, 2017 (quarter ended March 31, 2017)
Second quarter, 2017 (quarter ended December 31, 2016)
First quarter, 2017 (quarter ended September 30, 2016)
SEDAR® Filings
Loading data...

Stock Performance

-
Loading...
Display Events
 
 
 
 
Chart Style
Analyst Coverage
Firm Analyst E-mail Phone
Edison Investment Research Maxim Jacobs MJacobs@edisongroup.com +1 (646) 653-7027